12:00 AM
 | 
Jun 19, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Hemolink: Phase III

A preliminary analysis of HML's 298-patient Phase III trial in the U.K. and Canada showed a low rate of donor red blood cell transfusions, the primary end point, in both the Hemolink and...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >